Klin Farmakol Farm. 2018;32(3):34-37 | DOI: 10.36290/far.2018.031

Amiodarone induced acute hepatotoxicity during intravenous application

Jana Ďuricová1,2, Marcela Káňová3,4, Ivana Kacířová1,2
1 Oddělení klinické farmakologie, Ústav laboratorní diagnostiky, FN Ostrava
2 Ústav klinické farmakologie, Lékařská fakulta, Ostravská univerzita, Ostrava
3 Klinika anesteziologie, resuscitace a intenzivní medicíny, FN Ostrava
4 Ústav fyziologie a patofyziologie, Lékařská fakulta, Ostravská univerzita, Ostrava

Amiodarone is considered a very effective agent in the treatment of supraventricular and ventricular arrhythmias. It has a goodhaemodynamic profile with a low arrhythmogenic risk. However, its use is associated with many cardiac and extracardiac adverseeffects. Hepatotoxicity during long-term amiodarone administration is relatively frequent. Asymptomatic elevation of transaminasesis reported with incidence about 25 %, with normalisation after dose reduction or amiodarone discontinuation. On the otherhand, acute hepatotoxicity during intravenous amiodarone application is rare. This article presents a case of a patient admittedto the intensive care unit of our hospital who developed acute hepatotoxicity shortly after intravenous amiodarone introductionwith a rapid recovery after amiodarone cessation.

Keywords: amiodarone, hepatotoxicity, intravenous application

Received: March 20, 2017; Accepted: March 30, 2017; Published: November 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďuricová J, Káňová M, Kacířová I. Amiodarone induced acute hepatotoxicity during intravenous application. Klin Farmakol Farm. 2018;32(3):34-37. doi: 10.36290/far.2018.031.
Download citation

References

  1. Hrudikova Vyskocilova E, Grundmann M, Duricova J, et al. Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017; 161(2): 134-143. Go to original source... Go to PubMed...
  2. McGovern B, Garan H, Kelly E, et al. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed). 1983; 287(6386): 175-180. Go to original source... Go to PubMed...
  3. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology. 1989; 9(5): 679-685. Go to original source... Go to PubMed...
  4. Rätz Bravo AE, Drewe J, Schlienger RG, et al. Hepatotoxicity during rapid intravenous loading with amiodarone: Description of three cases and review of the literature. Crit Care Med. 2005; 33(1): 128-134. Go to original source... Go to PubMed...
  5. Lahbabi M, Aqodad N, Ibrahimi A, et al. Acute hepatitis secondary to parenteral amiodarone does not preclude subsequent oral therapy. World J Hepatol 2012; 4(6): 196-198. Go to original source... Go to PubMed...
  6. Fonseca P, Dias A, Gonçalves H, et al. Acute hepatitis after amiodarone infusion. World J Clin Cases. 2015; 3(10): 900-903. Go to original source... Go to PubMed...
  7. Grecian R, Ainslie M. Acute hepatic failure following intravenous amiodarone. BMJ Case Rep. 2012; 2012: 1-3. Go to original source... Go to PubMed...
  8. Chan AL, Hsieh HJ, Hsieh YA, et al. Fatal amiodarone-induced hepatotoxicity: a case report and literature review. Int J Clin Pharmacol Ther. 2008; 46(2): 96-101. Go to original source... Go to PubMed...
  9. Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol. 1990; 21(1): 59-67. Go to original source... Go to PubMed...
  10. Clinical and Research Information on Drug-Induced Liver Injury. [Online]. [20. 2. 2018]. Dostupné z: http://livertox.nlm.nih.gov.
  11. Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut. 1993; 34(4): 565-566. Go to original source... Go to PubMed...
  12. Balistreri WF, Farrell MK, Bove KE. Lessons from the E-Ferol tragedy. Pediatrics. 1986; 78(3): 503-506. Go to original source... Go to PubMed...
  13. Gregory SA, Webster JB, Chapman GD. Acute hepatitis induced by parenteral amiodarone. Am J Med. 2002; 113(3): 254-255. Go to original source... Go to PubMed...
  14. Simon JP, Zannad F, Trechot P, et al. Acute hepatitis after a loading dose of intravenous amiodarone. Cardiovasc Drugs Ther. 1990; 4(6): 1467-1468. Go to original source... Go to PubMed...
  15. van Tellingen O, Beijnen JH, Verweij J, et al. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice. Clin Cancer Res. 1999; 5(10): 2918-2924.
  16. Jaiswal P, Attar BM, Yap JE, et al. Acute liver failure with amiodarone infusion: A case report and systematic review. J Clin Pharm Ther. 2018; 43(1): 129-133. Go to original source... Go to PubMed...
  17. Breuer HW, Bossek W, Haferland C, et al. Amiodarone-induced severe hepatitis mediated by immunological mechanisms. Int J Clin Pharmacol Ther. 1998; 36(6): 350-352.
  18. Lu J, Jones AD, Harkema JR, et al. Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor-alpha. Toxicol Sci. 2012; 125(1): 126-133. Go to original source... Go to PubMed...
  19. Morelli S, Guido V, De Marzio P, et al. Early hepatitis during intravenous amiodarone administration. Cardiology. 1991; 78(3): 291-294. Go to original source... Go to PubMed...
  20. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore). 2003; 82(6): 392-406. Go to original source... Go to PubMed...
  21. Gluck N, Fried M, Porat R. Acute amiodarone liver toxicity likely due to ischemic hepatitis. Isr Med Assoc J. 2011; 13(12): 748-752. Go to PubMed...
  22. Guglin M. Intravenous amiodarone: offender or bystander? Crit Care Med. 2005; 33(1): 245-246. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.